FHI 360

- Daré Bioscience and Theramex have entered into a co-development agreement for Casea S, a first-in-category biodegradable contraceptive implant designed to last 18-24 months. - The innovative implant eliminates the need for surgical removal, addressing a key barrier in current contraceptive implants while offering women a convenient, long-acting contraceptive option. - A foundation-funded Phase 1 trial is currently underway to evaluate the pharmacokinetics, removability, safety, and tolerability of Casea S.

Feb 22, 2025

Back to Organizations

FHI 360

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (60)

Casea S Contraceptive Implants (Casea S) Trial

Levonorgestrel Intrauterine System Effects on Hemoglobin and Serum Ferritin Among Anemic Women in Kenya

The CATALYST Study

Eswatini Ring Study: Increasing PrEP Options for Women

evonorgestrel Intrauterine System effect on Anemia: LISA Trial

REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire

Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

Community-based Nutrition Program Effectiveness Evaluation in Afghanistan

Approvals

News

Daré Bioscience and Theramex Partner to Develop Novel Biodegradable Contraceptive Implant